Navigation Links
Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Date:9/19/2007

mg twice daily, steady-state mean trough concentrations ranged from approximately 150 -- 300 ng/ml, which are well above the EC50 (concentration required for 50% inhibition of viral replication) of RDEA806 (EC50 = 1.67 ng/ml).

Evaluation of the drug-drug interaction liability, in vitro and in vivo, demonstrated that RDEA806 is unlikely to be an inducer or inhibitor of major P450 enzymes or be affected by CYP3A4 inhibitors. When given together with ritonavir, an HIV protease inhibitor and potent inhibitor of CYP3A4, plasma levels of RDEA806 were not significantly altered. These data support preclinical data that RDEA806 may have a reduced potential for drug-drug interactions, which could ultimately lead to a safer and more convenient treatment option for patients and physicians.

"We recognize the need for new HIV drugs that demonstrate potent antiviral activity against a wide range of viral isolates, including those that are resistant to currently available NNRTIs, and that show improved safety, tolerability and reduced potential for drug-drug interactions. Yesterday's presentation of the broad spectrum of antiviral activity of RDEA806 demonstrated its in vitro activity against the majority of HIV strains carrying key reverse transcriptase mutations, including coverage of the 10 most prevalent strains of HIV found in patients failing therapy with efavirenz, marketed as Sustiva(R) by Bristol-Myers Squibb*. Based on this very favorable preclinical profile, the excellent tolerability and the high levels of exposure obtained with oral dosing in Phase 1 studies, we are moving forward to conduct a Phase 2a proof-of-concept study in HIV-infected patients, which we plan to initiate before the end of this year. The terminal half-life of up to 13 hours also gives us the opportunity to evaluate once-daily dosing in Phase 2a," said Barry D. Quart, PharmD, President and CEO.

About RDEA806

RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... June 24, 2015 ... addition of the "2015 Strategies in the ... This new 175-page report provides analysis ... diabetes (strips and meters), pregnancy, ovulation, and occult ... regulatory requirements, technologies, and competitive profiles. ...
(Date:7/1/2015)... KONG and FT LAUDERDALE, Florida ... Inc. ("OrbusNeich"), a designer, developer, manufacturer and marketer of innovative ... that on May 13, 2015, it prevailed in a final ... European Patent EP 1 341 482 - STENT HAVING HELICAL ... of review in the EPO and has been upheld as ...
(Date:7/1/2015)... , July 1, 2015 Dynatronics ... manufacturer and marketer of rehabilitation and physical therapy ... $4,025,000 private placement financing led by affiliates of ... equity investor focused on the healthcare industry. The ... organic growth and pursue potential strategic acquisitions.  ...
Breaking Medicine Technology:2015 Strategies in the Home/Self Testing Market 2OrbusNeich Announces Favorable Ruling from the European Patent Office and Initiation of Litigation Against Terumo Corporation 2Dynatronics Announces Completion Of $4,025,000 Private Placement Led By Prettybrook Partners 2Dynatronics Announces Completion Of $4,025,000 Private Placement Led By Prettybrook Partners 3
... Corporation (NYSE: CVS ) today announced that ... repurchase program for up to $4.0 billion of the ... is effective immediately, permits the company to effect the ... open market repurchases, privately negotiated transactions, accelerated share repurchase ...
... Inc. (Pink Sheets: GATA ) announced on August 15, ... are currently processing, and they are expecting this number to increase ... company expects to be able to convert at least two thirds ... The company also stated that due to the ...
Cached Medicine Technology:CVS Caremark Corporation Announces New Share Repurchase Authorization for up to $4 Billion of Common Stock 2CVS Caremark Corporation Announces New Share Repurchase Authorization for up to $4 Billion of Common Stock 3Groupe Athena, Inc. Clarifies Previous Guidance 2Groupe Athena, Inc. Clarifies Previous Guidance 3
(Date:7/1/2015)... , ... July 01, 2015 , ... Dr. Surya Challa ... July 6th on WAVY-TV’s The Hampton Roads Show to discuss non-invasive CoolSculpting . ... and exercise fall short. , CoolSculpting fat reduction utilizes Cryolipolysis to literally freeze ...
(Date:7/1/2015)... ... July 01, 2015 , ... During ... Posey (Manager, National Sales Training and Development) and Chuck Corso (Associate Sales Trainer) ... in Phoenix, AZ. LTEN brings together learning and development professionals from more than ...
(Date:7/1/2015)... ... ... Convoy of Hope will partner with local businesses, churches, government agencies ... at Spring Lake Park High School. , During the celebration, Convoy of Hope and ... and services including free food, health services, family portraits, job services, a carnival and ...
(Date:7/1/2015)... ... July 01, 2015 , ... Element Blue ™, a ... that it has received trademark protection for its SensorInsight® computer software platform. SensorInsight® ... from multiple sources providing an environment where users can view and compare real-time ...
(Date:7/1/2015)... Arizona (PRWEB) , ... July 01, 2015 , ... Amada ... opened a new office in the greater Phoenix area – their Mesa, Arizona ... move to senior care with their purchase of the rights to the area after ...
Breaking Medicine News(10 mins):Health News:Dr. Surya Challa of Chesapeake Vein Center and MedSpa Will be Featured on The Hampton Roads Show on WAVY-TV 2Health News:Dr. Surya Challa of Chesapeake Vein Center and MedSpa Will be Featured on The Hampton Roads Show on WAVY-TV 3Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 2Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 3Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 4Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:Amada Senior Care Expands to Greater Phoenix Area 2
... has tried to analyze the many reasons why some teen ... with IVF treatments //. In his reading, they are just ... be ridiculed. ,Laurence Shaw, the deputy medical director ... the opinion that, it is the internal program charted by ...
... IT is a general occurrence that people living in ... than those who stay in the opposite //. ... and find a close link and scientific backing to ... societies with better hygiene have higher rates of allergy ...
... suggested by researchers that being exposed to too much ... chance of developing breast tumours //. Women particularly those ... considered to be of particularly risk. ,For ... Cancer Institute and National Institute of Environmental Health Sciences, ...
... a tool used to develop human disease research, now proved ... //complex virus - the vaccinia virus, which is used in ... for Allergy & Immunology (LIAI). ,Researchers at ... have used it to successfully predict immune response to one ...
... destroy viruses due to their protective protein cover which protects ... harmful //. ,Tackling this problem, scientists at the ... of the European Molecular Biology Laboratory (EMBL) in Grenoble have ... of a protein that allows the rabies virus to be ...
... in India open to acting in B'wood Sydney, Sabrina ... represent Australia in the Miss World contest, says she is ... of non-Australian parentage to win the Miss Australia title last ... a Lebanese father. ,Sabrina, who supports a charity ...
Cached Medicine News:Health News:Protected Environment v/s Unprotected Affect Hygiene Health Immunity 2Health News:Protected Environment v/s Unprotected Affect Hygiene Health Immunity 3Health News:Protected Environment v/s Unprotected Affect Hygiene Health Immunity 4Health News:Exposure To Artificial Light Could Be Cancerous 2Health News:Bioinformatics Made a Boon In Immune Response Study - LIAI Finds 2Health News:Bioinformatics Made a Boon In Immune Response Study - LIAI Finds 3
... extensive line of affordable, high-quality light guide ... light sources to provide optimal brightness during ... and durable design give you the flexibility ... efficiently. And each is fully-autoclavable so they ...
Used under fluoroscopy for initial location and positioning of the renal collecting system throughout a percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
The Linvatec 3mm and 5mm Universal Light Guides are autoclavable. They offer flexibility, superior light transmission, and universal fittings in a lightweight package....
ACMI™ offers an assortment of fiberoptic light guides, high transmission autoclavable fiberoptic light guides, and light guide adapters to connect our scopes to other manufacturers' light sourc...
Medicine Products: